contact us  /  email
about us


During their long careers in venture capital, members of the team have been involved in the management of over 5 venture capital partnerships through multiple market cycles.  Including their activities at previous firms, the team has been involved with over 50 healthcare investments (originating many of these deals), many of which have been acquired or completed IPOs.  The team led a number of successful investments during their tenure at Asset Management Company, and continues to manage several of these investments.

BioMimedica is developing a new approach to joint repair through the use of synthetic cartilage. *Private

BiPar is a biopharmaceutical company developing a new class of cancer therapies based on a novel mechanism with broad therapeutic potential against a wide range of cancers. *Acquired by sanofi-aventis (NYSE: SNY)

Chimerix develops new broad spectrum anti-viral treatments that are focused on infectious disease such as smallpox, HIV, cytomegalovirus, and adenovirus. *2013 IPO (NASDAQ: CMRX)

Coherus Biosciences is biosimilar-focused, biologics platform company with the cutting-edge analytics, process science, and clinical and regulatory capabilities to develop and commercialize high-quality biosimilar therapeutics worldwide. *2014 IPO (NASDAQ: CHRS)

Enteric has developed minimally invasive surgical treatments for gastro-esophageal reflux disease ("GERD"). *Acquired by Boston Scientific (NYSE: BSX)

EndoVx is developing a novel medical device system for non-invasively treating obesity. *Private

Fusion Medial developed surgical sealants to halt arterial bleeding. *Acquired by Baxter International (NYSE: BAX)

InteKrin Therapeutics is pursuing the clinical development of therapeutics for metabolic and immune disorders. *Acquired by Coherus Biosciences (NASDAQ: CHRS)

Invuity, Inc. is a medical technology company focused on developing and marketing advanced photonics devices to improve the ability of surgeons to illuminate and visualize the surgical cavity during open minimally invasive and minimal access surgery. *2015 IPO (NASDAQ: IVTY)

iScience Interventional has develop and is marketing an image-guided surgical system for the treatment of glaucoma. *Private

Koronis Pharmaceuticals develops technologies for the prevention and treatment of chronic viral diseases: HIV, HBV and HCV. *Private

MicroVention developed catheter-based technologies for the endovascular treatment of cerebral and peripheral vascular diseases. *Acquired by Terumo Corporation (Japan)

Novare Surgical is a developer of proprietary medical devices for temporary occlusion management and one-port endoscopic surgery.
*Assets were acquired by several companies for cash and future royalties and proceeds distributed to shareholders.

Proteus Digital Health has developed digital health feedback technology integrated into ingestible products. *Private

Sonoma Orthopedics has developed and is marketing a unique implant device for fixation of long bone fractures. *Private

Trivascular developed next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). *Acquired by Boston Scientific (NYSE: BSX)

© Helix Ventures 2008 – 2015   /   about us   /   portfolio   /   team   /   news   /   contact us